TARPEYO (budesonide) delayed release capsules APPROVED TO REDUCE THE LOSS OF KIDNEY FUNCTION IN ADULTS WITH IgA NEPHROPATHY WHO ARE AT RISK FOR THEIR DISEASE GETTING WORSE
TARPEYO received full FDA approval in December 2023.
TARPEYO is a prescription medicine for IgAN. It is the first and only medicine FDA-approved to reduce the loss of kidney function in adults with IgAN who are at risk for their disease getting worse. It is not known if TARPEYO is safe and effective in children. TARPEYO was studied under the name NEFECON.
Visit Tarpeyo.com to learn more.
FREQUENTLY ASKED QUESTIONS
WHAT IS TARPEYO?
TARPEYO is a prescription medicine for IgAN. It is the first and only medicine FDA approved to reduce the loss of kidney function in adults with IgAN who are at risk for their disease getting worse. It is not known if TARPEYO is safe and effective in children.
WHEN WAS TARPEYO APPROVED?
TARPEYO received full FDA-approval in December 2023 and is available by prescription. TARPEYO was initially approved under accelerated approval in December 2021.
WHEN IS TARPEYO AVAILABLE?
TARPEYO is available today. Patients should consult their doctors if they have any questions about this treatment option. This approval does not change the way patients should take TARPEYO or how they need to get TARPEYO, through a prescription from their doctor.
HOW IS TARPEYO THOUGHT TO WORK?
TARPEYO is designed to deliver treatment to an area of the gut thought to play a role in IgA Nephropathy. Types of cells in the gut are thought to be responsible for the production of IgA1. These types of IgA1 can build up in the kidneys and cause IgA Nephropathy. TARPEYO can reduce the amount of this antibody.*
*It has not been established to what extent the efficacy of TARPEYO is from local effects (in the gut) vs systemic effects (in circulation).
WHAT WERE THE RESULTS OF THE CLINICAL TRAIL FOR TARPEYO?
Talk with your doctor for more information about the clinical trial results.
In a clinical trial with 364 IgA nephropathy patients, TARPEYO (taken for 9 months with 15 months
off-treatment observation) plus blood pressure medication (n=182) was compared to blood
pressure medication alone (n=182). The change in estimated glomerular filtration rate (eGFR, a
measure of kidney function), was assessed at 2 years compared to baseline.
DOES TARPEYO HAVE TO BE TAKEN FOR EVERY DAY FOR THE REST OF MY LIFE?
TARPEYO is a once-daily oral medicine with a 9-month recommended treatment course.
CAN TARPEYO BE TAKEN IN ADDITION TO OTHER MEDICATION?
TARPEYO was studied in addition to blood pressure medicine. It is important to take TARPEYO
exactly as your healthcare provider tells you. Patients should talk to their doctor to see how
TARPEYO could fit into their existing treatment plan.
WHERE CAN I FIND OUT MORE INFORMATION ON TARPEYO?
For more information on TARPEYO, talk to your doctor or visit TARPEYO.com. You can also call
TARPEYO Touchpoints at 1-833-444-8277 from 8 am to 8 pm ET, Monday through Friday.
